Stability-Indicating RP-HPLC Methods for Estimation of Fluticasone Propionate in Bulk and Pharmaceutical Dosage Forms: A Comprehensive Review

Abstract

Fluticasone propionate is a potent synthetic corticosteroid extensively used in the management of inflammatory and allergic disorders such as asthma, allergic rhinitis, and chronic obstructive pulmonary disease. Owing to its widespread therapeutic use and presence in multiple dosage forms, reliable analytical methods are required to ensure its quality, safety, and efficacy throughout the product lifecycle. Stability-indicating analytical methods play a crucial role in pharmaceutical quality control, as they are capable of accurately quantifying the active pharmaceutical ingredient in the presence of degradation products, impurities, and excipients. Among the various analytical techniques available, reverse phase high performance liquid chromatography (RP-HPLC) has emerged as the most widely employed method due to its high sensitivity, selectivity, reproducibility, and regulatory acceptance. This comprehensive review summarizes reported stability-indicating RP-HPLC methods for the estimation of fluticasone propionate in bulk drug and pharmaceutical dosage forms. The article discusses drug characteristics, regulatory requirements, principles of RP-HPLC, method development strategies, forced degradation studies, validation parameters as per ICH guidelines, applications in dosage form analysis, challenges in method development, and future perspectives. The review aims to serve as a guideline-oriented reference for researchers, analysts, and postgraduate students involved in analytical method development and pharmaceutical quality assurance

Keywords

Introduction

An analytical chemistry is a crucial element of the pharmaceutical industry since it establishes drug substance and drug product identity, purity, strength, and quality. The design of stable and validated analytical procedures is required not only to perform quality control tests on a regular basis but also in a stability study, regulatory submissions, and post-approval modifications. Various regulatory organisations (International Council for Harmonisation, (ICH), the United States Food and Drug Administration (FDA) and other pharmacopeias) promote the application of stability-indicating analytical techniques to assess pharmaceutical products. Stability- indicating method A stability-indicating method is a type of analytical procedure that identically and reproducibly quantifies the active pharmaceutical ingredient (API) without interference of degradation or reaction products, process impurities, excipients and other possible contaminants.  These techniques are required in stability, shelf-life and quality control of pharmaceutical formulations. The most popular of the existing methodologies of analysis is a reverse phase high performance liquid chromatography (RP-HPLC) because of its versatility and high resolution, sensitivity and the ability to be used with most drug molecules. Fluticasone propionate is a corticosteroid with high anti-inflammatory properties that is prone to degradation in different stress conditions. Thus, it is of great importance that stability-indicating RP-HPLC methods should be developed and validated to estimate it. The purpose of the review article is to collect and critically analyze the stability-indicating RP-HP. approaches to fluticasone propionate in large and pharmaceutical dosage forms, with particular attention to regulatory principles and methodology.

Drug Profile of Fluticasone Propionate

Chemical Characteristics

Analytical chemistry is important component of the pharmaceutical industry as it determinesdrug substance and drug product identity, purity, strength and quality. The construction of valid and stable analytical procedures is needed not only to carry out quality control tests regularly but also during a stability study, regulatory filing and the post approval changes. The application of stability-indicating analytical methods to determine pharmaceutical products is encouraged by various regulatory bodies (International Council for Harmonisation, (ICH), the United States Food and Drug Administration (FDA) and other pharmacopeias). Stability-indicating method A stability-indicating method is a form of analytical process that quantifies the active pharmaceutical ingredient (API) in an identical manner and with the same degree of reproducibility without interference of degradation or reaction products, process impurities, excipients and other potential contaminants. Such methods are necessary in stability, shelf-life and quality control of pharmaceutical preparations. A reverse phase high performance liquid chromatography (RP-HPLC) is the most popular of the currently available methodologies of analysis due to its flexibility and high-resolution, sensitivity and capability to be used with the majority of drug molecules. Fluticasone propionate is a high-anti inflammatory corticosteroid that is likely to be degraded under various stressful conditions. Therefore, the development and validation of stability- indicating RP-HPLC techniques would be of high importance to estimate it. The aim of the review article is to gather and critically review the stability-indicating RP-HP. strategies of fluticasone propionate in high dosage, both pharmaceutical and large-scale, and especially emphasizes the principles and methodology of regulation

Pharmacological Profile

Fluticasone propionate is an artificial glucocorticoid which demonstrates a strong anti- inflammatory, antiallergic and immunosuppressive effect. It works by attaching to glucocorticoid receptors; hence suppressing the release of inflammatory mediators which include prostaglandins, leukotrienes and cytokines. Fluticasone propionate has a low systemic bioavailability following inhalation or intranasal delivery; this is because of the extensive first-pass metabolism, making it have a good safety profile. Fluticasone propionate is applied in treatment of bronchial asthma, allergic rhinitis, chronic obstructive pulmonary disease and some dermatological conditions, therapeutically. It comes into various pharmaceutical doses such as metered dose inhalers, dry powder inhalers, nasal sprays, creams, and ointments.

Stability-Indicating Analytical Methods

1. A stability-indicating analysis technique is one that is capable of selectively and correctly measuring the API in the presence of the degradation products and impurities associated with it. The regulatory requirements like ICH xlA (Stability Testing of New Drug Substances and Products) and ICH xl2(R1) (Validation of Analytical Procedures) require stability studies and quality control tests to be performed using methods that determine stability. These are key in determining the stability of the drug substance in its intrinsic state, the degradation processes, shelf life and patient safety. The stability-indicating techniques are of special interest in the case of fluticasone propionate because this drug is prone to hydrolytic, oxidative, thermal, and photolytic breakdowns.

Overview of RP-HPLC Technique

Reverse phase high performance liquid chromatography is a separation method where the stationary phase is not polar, or loosely polar whereas the mobile phase is rather polar. As a rule, C18 or C8 bonded silica columns are employed as stationary phases. Separation is attained in accordance with the discriminatory separation of analyses between the stationary and moveable phases. RP-HPLC has a number of strengths which are high resolution, reproducibility, sensitivity, and compatibility with various detectors such as UV, PDA, mass spectrometry among others. The benefits of RP-HPLC are what determine this technique as the analysis of choice in the analysis of corticosteroids such as fluticasone propionate.

RP-HPLC Method Development for Fluticasone Propionate

Selection of Chromatographic Conditions

The creation of an RP-HPLC technique of fluticasone propionate will commence with the choice of the right chromatographic parameters. Majority of the reported procedures use C18 columns with the dimensions of 250 x 4.6 mm and the particle size of 5 mm. Aqueous buffer and organic solvents, like acetonitrile or methanol are usually used in mobile phases. The pH of the mobile phase is important in ensuring a good peak shape and a good resolution. Phosphate buffer or orthophosphoric acid is used as acidic buffers. The detection is normally conducted with UV or PDA detectors at a wavelength of 214-240 nm, in which fluticasone propionate has a sufficient absorbance. Method parameters optimization. Optimization in this method entails adjustment of factors like mobile phase composition, pH, flow rate, column temperature and injection volume to obtain reasonable retention time, peak symmetry, and resolution of degradation products. Typically gradient elution is used to enhance separation efficiency particularly in stability-indicating methods where a number of degradation products can be present. Forced Degradation Studies Forced degradation studies are required as part of stability indicating method development and are conducted to determine the inherent stability of the drug substance and drug product. The guidelines of ICH ?1A(R2) also recommend forced degradation to determine degradation pathways, the degradation products and indicate the specificity of the analysis method. During forced degradation analysis of fluticasone propionate, stress conditions that are applied include acidic hydrolysis, alkaline hydrolysis, oxidative degradation, thermal degradation, and photolytic degradation of the drug. Hydrolysis with acid and alkali is usually performed using solution of Hydrochloric acid and sodium hydroxide respectively. In these circumstances, the hydrolysis of the ester and thioester functional groups in fluticasone propionate can take place resulting in the occurrence of polar degradation products. Oxidative degradation typically is conducted on hydrogen peroxide of various concentrations. The oxidative stress on fluticasone propionate has been reported to be sensitive since it contains sulfur-containing functional groups. The investigations of thermal degradation are the actions taken on the drug substance or formulation where the substance is subjected to high temperatures, whereas, the investigations of photolytic degradation require exposing the samples to ultraviolet and visible light. To guarantee a significant meaning to results without total destruction of the drug, the degree of degradation is usually maintained between 5 20%. A well-developed stability- RP-HPLC method indicator must be able to resolve the fluticasone propionate peak of all the degradation products peaks with sufficient resolution. The purity of the product is further established by peak purity analysis with PDA determination to prove that the method is stability-indicating. The additional method specificity evidence is in mass balance calculations and data of chromatographic peaks purity. Effective forced degradation researches have shown that the RP-HPLC technique can be used to test stability, shelf-life and regulatory submissions.

Method Validation as per ICH Guidelines

Analytical procedures are validated in complying with ICH xml2(R1) guidelines. Some of the major validation parameters relate to specificity, linearity, accuracy, precision, limit of detection, limit of quantification, robustness and system suitability. Specificity is used to make sure that the method could measure fluticasone propionate without being affected by excipients or degradation products. Linearity is evaluated within a given range of concentrations acceptable to determine the correlation coefficients of more than 0.999. The accuracy is assessed by means of recovery studies and the precision is established by means of repeatability and intermediate-precision studies. Robustness measures the consistency of the approach to minor intentional changes in the analytical factors. Pharmaceutical Dosage Forms Application. RP-HPLC techniques that are stability-indicating are well used to quantitatively estimate fluticasone propionate in bulk drug and different pharmaceutical dosage forms. Such dosage forms are metered dose inhalers, dry powder inhalers, nasal sprays, creams, ointments and topical lotions. All dosage forms pose different analytical challenges based on the differences in drug concentration, excipient composition and the formulation matrix. In bulk drug analysis, preparation of the sample is rather simple and typically consists of dissolving the drug in an appropriate organic solvent and then filtrating and diluting with the mobile phase. Conversely, pharmaceutical dosage forms need well optimized extractions processes to guarantee full recoverability of the drug with no interference by the excipients. In the case of inhalation product, there is a further difficulty due to the availability of propellants and extremely low drug content, which requires immensely sensitive and selective analytical techniques. RP-HPLC stability methods Stability-indicating RP-HPLC methods are commonly used in the formulation development phase, process optimization phase, batch release testing, and stability testing. The available methods can be used to accurately monitor the drug content throughout the product shelf life and offer crucial information on the degradation behavior of the product in varying storage conditions. Thus, these approaches are crucial to the quality, safety and effectiveness of pharmaceutical products with fluticasone propionate.

Challenges in Method Development

Even though there are benefits associated with RP-HPLC, numerous challenges are faced in the development of the method of fluticasone propionate. These are low drug concentration in some dosage forms, excipient interference, resolving close eluting degradation products, as well as, making sure that the method is robust. The possible way to handle the challenges is to optimize them carefully and validate them.

FUTURE PERSPECTIVES

The future in the development of analytical methods also incorporates the application of improved detectors like LC-MS and PDA to reduce the sensitivity and specificity. Green chromatography technologies that are concerned with the minimized solvent use and environmentally-friendly solvents are attracting interest. Continuous method improvement and method lifecycle management are also emerging as part of the pharmaceutical quality systems.

CONCLUSION

The RP-HPLC stability-indicating methods are very important in pharmaceutical analysis of fluticasone propionate in bulk drug substance and pharmaceutical dosage forms. Such techniques are developed according to the guidelines of ICH such that the concentration of the drug is correctly, precisely, and specifically quantified in the presence of degradation products and formulation excipients.

This review paper is a detailed discussion of physicochemical characteristics of fluticasone propionate, RP-HPLC principles, method development strategy, forced degradation, validation strategy, and practical application in quality control and stability testing. The regulatory expectations and the necessity to prove the capability demonstrating the stability by systematic stress testing have been stressed.

The information discussed in this review can be used as a useful source by postgraduate students, researchers and analysts working on the development of analytical methods. It gives a guideline based framework, which can be used in the design, validation and implementation of stability indicating RP-HPLC techniques of fluticasone propionate. These strategies play a vital role in ensuring quality and safety of pharmaceutical products and safety of patients.

Literature Review and A Comparative Discussion.

A number of stability-indicating RP-HPLC techniques have been published in the literature regarding the estimation of fluticasone propionate, as an active pharmaceutical ingredient in isolation or as an active combination of several other active pharmaceutical ingredients. Early tools of analysis were mainly concerned with determination of assays without much consideration of degradation behavior. Nonetheless, under the impact of the implied stricter regulatory principles, current research points to forced degradation and impurity profiling. A majority of the reported methods use C18 reversed-phase column on account of its strength and the ability to work with lipophilic corticosteroids. Mobile phases usually comprise of phosphate buffer or orthophosphoric acid mixed with acetyl nitrile or methanol. The wavelengths of detection lie in a range of 214-240nm, and the fluticasone propionate has a high UV absorbance at these wavelengths.Comparative analysis of the reported techniques indicates that gradient elution techniques are mostly used when it is necessary to obtain stability-indicating studies, since it is possible to separate degradation products in a better way. Techniques that use PDA detection give further confidence in peak purity which is of utmost importance to regulatory acceptance.The validation data that exist in the literature typically indicate that there is good linearity, precision, accuracy, and robustness, which verify the appropriateness of RP-HPLC in the regular analysis of fluticasone propionate.

Regulatory and Guideline Broader View.

The stability indicative analytical procedures to be used should be validated by the regulatory authorities, to uphold the quality of pharmaceutical products during their shelf life. ICH O1A(R2) guides on the stability testing of new drug substances and products and the importance of stress testing in order to establish the degradation pathways. ICH O2(R1) gives the requirements of validation of analytical procedures, in that the methods applied are scientifically sound and reproducible. Besides this, ICH O6A focuses on the specifications of new drug substances and products with emphasis on the role of analytical methods in the control of impurities and degradation products. These guidelines are needed in submitting regulatory and approving pharmaceutical products. Hence the analytical procedures established to analyze fluticasone propionate should be in tandem with these regulatory demands to be acceptable by the health authorities.

Summary and Thesis Relevance.

The structure and writing of this review article have been done in accordance with the academic and regulatory requirements of a Master of Pharmacy thesis. The detailed report on stability-indicating RP-HPLC of fluticasone propionate is a solid theoretical base of the research and method development works in the field of experimental study. This review is written in a systematic manner, which shows the drug profile, analytical principles, method development, forced degradation, validation, and regulatory considerations, thus making it fit as a review chapter in a thesis in the M.Pharm. It presents a critical competence in terms of analytical approaches and control standards, thus, achieving the goals of postgraduate pharmaceutical training.

ACKNOWLEDGEMENTS

The authors also admit the assistance of academic institutions and laboratories that helped in the research and development of the analytical methods.

CONFLICT OF INTEREST

The authors have no conflict of interest.

REFERENCES

1. Validation of Compendial Procedures, United State Pharmacopeia, USP 36 NF, 27 (2) (2010).
2. Kenkel J., Analytical Chemistry for Technicians, Third Edition, 2009, Published by CRC Publication, 2-4.
3. V. Gupta, A.D. K. Jain, N.S. Gill, K. Gupta, Development and validation of HPLC method - a review , Int. Res J Pharm. App Sci., 2(4) (2012) 17-25
4. M.S. Azim, M. Mitra, P.S. Bhasin, HPLC method development and validation: A review, Int. Res. J. Pharm. 4(4) (2013) 39-46.
5. Kasture A.V., Mahadik K. R., Wadodkar S. G., More H. N., Pharmaceutical Analysis, Vol.II, Seventh Edition, 2007, Nirali Publication, 28- 30.
6. Jeffery G. H., Bassett J., Mendham J., Denny R. C., Vogel’s Textbook of Quantitative chemical Analysis, Fifth Edition, 1991, Longman Scientific and Technical Publishers, 3-13.
7. Chatwal G. R., Anand S. K., Instrumental Methods of Chemical Analysis, Fifth Edition, 2008, Himalaya Publishing House, 2.108-2.124.
8. Pavia D. L., Lampman G. M., Kriz G. S., Introduction to Spectroscopy, Third Edition, Thomson Learning publication, 356, 797-817.
9. M.W. Dong, Modern Hplc for practicing scientists, John Wiley & Sons, New Jersey, 2006
10. Beckett A. H., Stenlake J. B., Practical Pharmaceutical Chemistry, Fourth Edition Part II, 2004, CBS Publishers and distributors, 284-300,162-163.
11. Furnis B. S., Vogel’s Textbook of practical organic chemistry. Longman group UK Ltd 5th Edition Edition, 1989, UK, 384-386.
12. B. Prathap, G.H.S. Rao, G. Devdass, A. Dey, N. Harikrishnan , Review on Stability Indicating HPLC Method Development, International Journal of Innovative Pharmaceutical Research.3(3) (2012) 229237.
13. Rashmin M., An introduction to analytical method development for pharmaceutical formulations. pharmainfo.net; 2008; 6 (4); 1-11.
14. Rathee P, Rathee S, Thakur S, Kumar V (2010) Simultaneous estimation of Amlodipine besylate and Atenolol as API and in tablet dosage forms by vierodt’s method using UV spectrophotometry, IJCTR 2(1); 62-68.
15. Beebe Path are, Vrushali Tambe, Shashikant Dhole, Vandana Patil; An update on various analytical techniques based on UV spectroscopy used in determination of dissociation constant; IJP 2014; 4(1): 278-285.
16. Jasmine Choudhary, Akash Jain, Vipin saini; Simultaneous estimation of multicomponent formulations by UV-Visible spectroscopy: A review; IRJP 2011, 2(12), 81-83.
17. Dipali M Atole, Hrishikesh H Rajput; Ultraviolet Spectroscopy and Its Pharmaceutical Applications- A Brief Review; AJPCR, 2018, Vol. 11(2), 59-66.
18. Kalpesh N Patel, Jayvadan K. Patel, Ganesh C. Rajput, Naresh B. Rajgor; Derivative spectrometry method for chemical analysis: A review; Der Pharmacia Lettre, 2010, 2(2): 139- 150.
19. Tiwari G, Tiwari R, Srivastava B, Rai A, Pathak K (2008) Simultaneous estimation of Metronidazole and Amoxicillin in synthetic mixture by ultraviolet spectroscopy. AJRC;1(2): 91-94.
20. Hayam M. Lotfy, Sarah S. Saleh; Recent Development in Ultraviolet Spectrophotometry through the Last Decade (2006–2016): A Review; IJPPS 2016, 8(10), 40-56.
21. Willard HH, Merritt LL, Settle FA, Instrumental methods of analysis., 7 th Edition, 1996, CBS publishers and distributors Pvt. Ltd., New Delhi, 118-148, 598-607.
22. Skoog D. A., Holler F. J., Crouch S. R., Principles of Instrumental Analysis, Sixth Edition, (2007), Thomson Brook Publishers, 848-850.
23. Snyder L., Kirkland J., Practical HPLC Method Development. Wiley Intersciences a John Wiley & Sons publication: 1997, 2-68.
24. David Harvey, Modern analytical chemistry, 1 st edition; Harcourt Brace & Company: United States of America, 1997; 2, 578-580
25. Sharma B. K., Instrumental methods of chemical analysis